ANDA Sponsors Fail To Knock Out Trintellix Active Ingredient Patent

IP Expiring In June 2026 Upheld As Valid By US District Court

 
• By Dean Rudge

Danish originator Lundbeck says it is “unthinkable” that proposed generic versions of its Trintellix treatment for major depressive disorder will find a way to the US market before 2027 following a US district court decision.

Gavel
Trintellix was the first treatment for acute major depressive disorder approved by the FDA • Source: Shutterstock

More from Generics

More from Products